Nitazoxanide #37959
Product Information
Product Usage Information
Nitazoxanide is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.08 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Product Description
| Molecular Weight | 307.3 g/mol |
| Purity | 98% |
| Molecular Formula | C12H9N3O5S |
| CAS | 55981-09-4 |
| Solubility | Soluble in DMSO at 50 mg/ml. |
Background
Nitazoxanide, also known as NTZ, is a broad-spectrum thiazolide antiparasitic agent that is a noncompetitive inhibitor of pyruvate:ferredoxin/flavodoxin oxidoreductases (PFORs) (1-3). This small molecule is an effective antiviral agent by activating protein kinase activated by double-stranded RNA (PKR), resulting in the phosphorylation of eukaryotic initiation factor 2 alpha (eIF2α). This method of influencing the host’s antiviral pathways increases the barrier to develop antiviral resistance (4). Nitazoxanide has shown anticancer activity in vivo by inhibiting oxidative phosphorylation and mitochondrial respiration. Treatment with Nitazoxanide leads to AMPK activation, inhibition of mTOR, and downregulation of c-Myc and Wnt signaling (5). Nitazoxanide has been found to be a particularly potent c-Myc inhibitor with IC50 values ranging between 10 nM to 500 nM in different cancer cell lines (1). Studies have shown that Nitazoxanide may be an effective treatment against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses (6).
- Fan-Minogue, H. et al. (2013) Mol Cancer Ther 12, 1896-905.
- White, C.A. (2004) Expert Rev Anti Infect Ther 2, 43-9.
- Hoffman, P.S. et al. (2007) Antimicrob Agents Chemother 51, 868-76.
- Keeffe, E.B. and Rossignol, J.F. (2009) World J Gastroenterol 15, 1805-8.
- Senkowski, W. et al. (2015) Mol Cancer Ther 14, 1504-16.
- Rossignol, J.F. (2016) J Infect Public Health 9, 227-30.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.